News

Hastings Tribune5mon
Agendia, Inc. presenta un'analisi di un 2024 coronato dal successo
L'altro abstract dell'ASCO è stato ACT/TC, e ha dimostrato la capacità di identificare i pazienti ad alto rischio che hanno risultati migliori con un regime con antracicline.
Cancer Research6y
Abstract P1-12-16: Risk factors for trastuzumab cardiotoxicity in a cohort of Mexican population - American Association for Cancer Research
Abstract. BACKGROUND: Advances in chemotherapy and target therapy have made treatment of breast cancer (BC) more effective; however, survivors of BC suffer an increased burden of cardiotoxicity. The ...
ascopubs.org15y
Multicentric observational study to assess clinical characteristics of HER2-positive breast cancer patients treated with adjuvant anti-HER2 therapy. - ASCO Publications
Antracicline and taxanes based combination was the most frequent chemotherapy in the neo-adjuvant (77%) and adjuvant setting (65%), especially in node-positive patients. Platinum-based chemotherapy ...
ascopubs.org20y
Impact of taxanes in association with anthracyclines in 1
Background: The real advantage of taxanes in adjunction to antracycline-based chemotherapy in 1 st line MBC is still unclear. We performed a comprehensive review (not a meta-analysis) (Simes, Stat Med ...